Biochemical Failure After Treatment of Testis Tumor

Basiri, Abbas; Radfar, Mohammad Hadi
January 2010
Urology Journal;Nov2010, Vol. 7 Issue 1, p59
Academic Journal
Case Study
The article presents a case study of a 37-year-old man presented with a hard large mass in the right testis. The patient's pathologic examination result reveals that he has teratoma along with choriocarcinoma and was followed up with laboratory tests and computed tomography (CT). It notes that the patient has underwent retroperitoneal lymph node dissection and was administered with postoperative chemotherapy using four courses of of bleomycin, etoposide, and cisplatin regimen.


Related Articles

  • Choriocarcinoma in a 73-year-old woman: a case report and review of the literature. Desai, Nisarg R.; Gupta, Shilpi; Said, Rabih; Desai, Priyal; Qun Dai // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Choriocarcinoma is a highly malignant tumor of trophoblastic origin. Most cases present within one year of the antecedent pregnancy (molar or non-molar). However, very rarely, choriocarcinoma can develop from germ cells or from dedifferentiation of endometrial carcinoma into...

  • Pure nongestational choriocarcinoma of the ovary: a case report. Youn Jin Choi; Keun Young Chun; Yong Wook Kim; Duck Yeong Ro // World Journal of Surgical Oncology;2013, Vol. 11 Issue 1, p1 

    Pure ovarian choriocarcinoma can be gestational or nongestational in origin. Nongestational choriocarcinoma of the ovary is extremely rare, and its diagnosis is very difficult during the reproductive years. We present a case of a 33-year-old woman diagnosed with pure nongestational ovarian...

  • Treatment and outcomes of primary intracranial teratoma. Lee, Yun-Ho; Park, Eun; Park, Young; Shim, Kyu-Won; Choi, Joong-Uhn; Kim, Dong-Seok // Child's Nervous System;Dec2009, Vol. 25 Issue 12, p1581 

    Until recently, postoperative adjuvant treatment for intracranial teratomas has remained controversial because of the rarity of the tumors and the heterogeneity of histologic types. To define optimal therapy modalities, we retrospectively analyzed the treatment of patients with intracranial...

  • Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors. Satya, Venkata; Attili, Suresh; Chandra, Rama C.; Anupama, G.; Loknath, D.; Bapsy, P. P.; Dadhich, Hermant K.; Babu, Govind K. // Journal of Cancer Research & Therapeutics;Jul-Sep2007, Vol. 3 Issue 3, p150 

    Background: In patients with small-volume disseminated disease of germ cell tumors, cure can be achieved with four cycles of bleomycin, etoposide, and cisplatin (BEP). However, around 20% of these cases are not curable. Strategies to improve cure rates have shown that none of the currently...

  • Antineoplastics.  // Reactions Weekly;3/10/2007, Issue 1142, p9 

    The article focuses on the cases of two men who developed azoospermia following chemotherapy with cisplatin, etoposide and bleomycin (BEP). It says that the first patient has suspected retrogade ejaculation and infertility after receiving the chemotherapy. No sperm was found on the ejaculate...

  • Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. T. de La Motte Rouge; P. Pautier; P. Duvillard; A. Rey; P. Morice; C. Haie-Meder; P. Kerbrat; S. Culine; F. Troalen; C. Lhommé // Annals of Oncology;Aug2008, Vol. 19 Issue 8, p1435 

    Background: Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women. Chemotherapy has dramatically improved the prognosis. Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor,...

  • Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). S Culine; P Kerbrat; A Kramar; C Théodore; C Chevreau; L Geoffrois; NB Bui; J Pény; A Caty; R Delva; P Biron; K Fizazi; J Bouzy; JP Droz // Annals of Oncology;May2007, Vol. 18 Issue 5, p917 

    Background: High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin. Patients and methods: Patients received either three cycles of BE500P or four cycles of E500P every 3 weeks. Disease was defined according to...

  • Bleomycin/cisplatin/etoposide.  // Reactions Weekly;10/31/2009, Issue 1276, p8 

    The article describes the case of a 25-year-old man with testicular cancer who developed neutrophilic eccrine hidradenitis after starting chemotherapy with bleomycin, cisplatin and etoposide. The man presented with a cystic lesion in his right armpit following the chemotherapy. The man was found...

  • Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). J. Wang; D. Short; N. J. Sebire; I. Lindsay; E. S. Newlands; P. Schmid; P. M. Savage; M. J. Seckl // Annals of Oncology;Sep2008, Vol. 19 Issue 9, p1578 

    Objectives: To evaluate the efficacy and toxicity of paclitaxel and cisplatin alternating with paclitaxel and etoposide doublet regimen (TP/TE), for salvage of patients with high-risk gestational trophoblastic neoplasia (GTN). Patients and methods: Twenty-four patients with GTN received TP/TE....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics